Captrust Financial Advisors Takes $754,000 Position in Celgene Corporation (NASDAQ:CELG)

Captrust Financial Advisors acquired a new stake in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,802 shares of the biopharmaceutical company’s stock, valued at approximately $754,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. State Street Corp increased its position in shares of Celgene by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after acquiring an additional 723,844 shares in the last quarter. Jennison Associates LLC increased its position in shares of Celgene by 1.2% in the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after acquiring an additional 156,864 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Celgene by 3.3% in the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after acquiring an additional 349,974 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Celgene by 3.6% in the second quarter. Ameriprise Financial Inc. now owns 9,874,214 shares of the biopharmaceutical company’s stock worth $1,282,369,000 after acquiring an additional 342,580 shares in the last quarter. Finally, Pioneer Investment Management Inc. increased its position in shares of Celgene by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after acquiring an additional 710,584 shares in the last quarter. 80.17% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently issued reports on CELG. Cann reissued a “buy” rating and issued a $166.00 price objective on shares of Celgene in a research report on Wednesday, November 22nd. TheStreet lowered shares of Celgene from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. BMO Capital Markets raised their price target on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Canaccord Genuity set a $140.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Thursday, November 16th. Finally, Oppenheimer set a $166.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $139.57.

Shares of Celgene Corporation (CELG) traded up $0.47 during trading hours on Monday, reaching $102.61. 5,470,354 shares of the company traded hands, compared to its average volume of 4,764,378. The company has a market cap of $81,380.00, a P/E ratio of 15.96, a PEG ratio of 0.79 and a beta of 1.77. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $1.58 EPS. sell-side analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.

In other news, Director Michael D. Casey sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Captrust Financial Advisors Takes $754,000 Position in Celgene Corporation (NASDAQ:CELG)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/captrust-financial-advisors-purchases-new-holdings-in-celgene-corporation-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply